不再迷惘的制药商：2025年并购额暴涨124%，巨头狂扫创新药资产

Core Insights - The sentiment among pharmaceutical companies attending the upcoming J.P. Morgan Healthcare Conference in San Francisco is significantly more relaxed compared to 2025, with previous uncertainties regarding drug pricing policies and tariffs largely dissipated [2][4] - The biopharmaceutical sector has seen a more than doubling of deal activity over the past year, with expectations for 2026 to surpass last year's performance [2][5] Group 1: Market Sentiment and Deal Activity - Pharmaceutical companies reached $130 billion in deals in 2025, a 124% increase from the previous year, with approximately 30 transactions exceeding $1 billion, marking a historical high [5] - The positive market reaction is attributed to an agreement with the White House aimed at lowering drug prices without significant adjustments to financial outlooks from related companies [4] Group 2: Acquisition Trends - Major pharmaceutical companies like Merck, Pfizer, and Bristol-Myers Squibb are under pressure to replenish their product pipelines as patents for blockbuster drugs are set to expire within the next five years, threatening over $300 billion in sales [8] - There has been a surge in public bidding wars for biotech firms developing potential blockbuster drugs, indicating a strong desire among CEOs to pursue acquisitions [9][10] Group 3: Investment Climate and IPO Outlook - The current high stock prices are encouraging CEOs to pursue mergers and acquisitions more aggressively, with a notable increase in competition for biotech companies [9] - Despite the optimistic outlook, rising valuations may deter potential buyers, leading to a cautious approach towards major acquisitions [11][12] - There is an expectation of a significant number of private biotech companies going public this year, with venture capital increasingly focusing on later-stage companies in anticipation of a more favorable IPO environment in 2026 [12]